IOVANCE BIOTHERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.61 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.70, a 52.51% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $3.58, a 58.08% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.54, a 72.87% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.94, a 43.93% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.24, a 67.86% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.97, a 41.96% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $4.91, a 40.77% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $8.29, a 62.79% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.61 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $1.70 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $2.24 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $2.33 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $2.61 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $3.58 10-Q · filed 2025-05-08 | ||||
| 2024-12-31 | $6.97 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $7.33 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $7.39 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $8.54 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $4.91 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $4.95 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $5.01 10-Q · filed 2023-08-08 | ||||
| 2023-03-31 | $4.94 10-Q · filed 2023-05-10 | ||||
| 2022-12-31 | $8.29 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $8.78 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | $8.89 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | $8.81 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | $22.28 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $23.29 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $24.38 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | $26.42 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $17.32 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $16.37 10-Q · filed 2021-11-04 | ||||
| 2020-06-30 | $16.20 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | $15.67 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $9.48 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $8.90 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $7.98 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | $6.99 10-Q · filed 2020-05-05 | ||||
| 2018-12-31 | $14.44 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $15.26 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | $15.26 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $15.52 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | $6.58 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $5.81 10-Q · filed 2017-11-02 | $6.46 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | $5.98 10-Q · filed 2017-08-03 | $6.83 10-Q · filed 2018-08-07 | $6.85 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | $7.36 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | $6.78 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | $8.97 10-Q · filed 2017-11-02 | $6.75 10-Q · filed 2017-11-02 | |||
| 2016-06-30 | $6.19 10-Q · filed 2017-08-03 | $5.68 10-Q · filed 2017-08-03 | |||
| 2015-12-31 | $8.77 10-K · filed 2018-03-12 | ||||
| 2014-12-31 | $6.66 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |